Association of GLP1 ‐receptor agonist use with liver disease progression, major cardiovascular events, and mortality in people with hepatic steatosis and diabetes

Documenti analoghi

• GLP ‐1 receptor agonists and cardiovascular events in metabolically healthy or unhealthy obesity
  di: Tommaso Bucci, et al.
  Pubblicazione: (2025)
• Real world data showed that the dual GLP gip agonist, Tirzepatide is associated with lower mortality, cardiovascular events and adverse kidney events compared with GLP‐1 analogue
  di: Iskandar Idris
  Pubblicazione: (2024)
• Sex differences in the efficacy of GLP ‐1 receptor agonists: A systematic review and meta‐analysis of cardiovascular and renal outcome trials
  di: Hasan Fareed Siddiqui, et al.
  Pubblicazione: (2025)
• Digital engagement enhances dual GIP / GLP ‐1 receptor agonist and GLP ‐1 receptor agonist efficacy: A retrospective cohort analysis of a digital weight loss service on outcomes and safety
  di: Hans Johnson, et al.
  Pubblicazione: (2025)
• Glucagon‐like peptide‐1 receptor agonists lower risk of cardiovascular and non‐cardiovascular mortality: A meta‐analysis of eleven cardiovascular outcome trials
  di: Yu Mi Kang, et al.
  Pubblicazione: (2025)